Read More: eGenesis Announces World’s First Successful Transplant of Genetically Engineered Porcine Kidney in a Living Patient


Paul Sekhri

Board Director
  • LinkedIn

Mr. Sekhri brings decades of experience leading life sciences companies, including those with a focus on immunology, and has been a director on more than 24 private and public company boards. He most recently served as the chief executive officer of eGenesis.

Before eGenesis, Mr. Sekhri came from Lycera Corp., where he served as president and chief executive officer. Prior to Lycera, he served as group executive vice president, global business development, and chief strategy officer for Teva Pharmaceuticals Industries, Ltd., and earlier, operating partner and head of the Biotechnology Operating Group at TPG Biotech. Previously, Mr. Sekhri founded Cerimon Pharmaceuticals where he served as president and chief executive officer.

Prior to founding Cerimon, he was president and chief business officer of ARIAD Pharmaceuticals. Earlier in his career, Mr. Sekhri held various senior positions at Novartis AG, including senior vice president, head of global search and evaluation, business development and licensing, and global head, early commercial development.

Mr. Sekhri completed graduate work in neuroscience at the University of Maryland School of Medicine in Baltimore and received his B.S. in zoology from the University of Maryland, College Park.

Paul Sekhri